N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, BELARUS, JAPAN, NYA ZEELAND, RYSSLAND, SYDAFRIKA, SYDKOREA, KANADA ELLER I NÅGON
Today, Peptonic Medical AB (“Peptonic”) publishes an operational update outlining the strategic actions and initiatives implemented and planned for the year. These efforts are expected
Peptonic Medical AB (“Peptonic”) today announces its decision to discontinue its Israeli subsidiary, a contract manufacturing organization (CMO) specializing in self-diagnostic tests. The decision will
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its
Peptonic Medical (publ) (“Peptonic”) is further strengthening its product portfolio with the launch of VagiVital Intimate Calming Gel, a specially formulated product designed to provide
Peptonic Medical (publ) (“Peptonic”) is expanding its portfolio of clinically proven intimate self-care products with the launch of VagiVital Active Glide, a water-based lubricant specifically
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) has received notification that the Australian patent office has granted the FOAM II patent. This patent provides broad protection for
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (“Peptonic”) today presents an operational update highlighting the strategic measures implemented during Anna Linton’s first 120 days as CEO. These efforts, aimed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) announces that the European Patent Office (“EPO”) has granted a patent for the relief of provoked vulvodynia (previously referred to
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) announces today changes within its organization. Global Business Director, Erik Sundquist, and Senior Advisor, Dan Markusson, will be leaving their
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announces the appointment of Jenni Björnulfson as the company’s new Chief Financial Officer (CFO). Jenni will assume the position on
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announces that the United States Patent and Trademark Office (“USPTO”) has granted patent (16238.0043U1) for the treatment and prevention of
Peptonic Medical AB (publ) (“Peptonic”) has signed an exclusive distribution agreement with FirstAid4All to launch Peptonic’s products in intimate self-care in Belgium, the Netherlands, and
Peptonic Medical AB (publ) (“Peptonic”) today announces that CFO, Albert Lindgren, is leaving the company to take on new challenges. Albert is expected to remain
Peptonic Medical AB (“Peptonic”) clarifies short term strategic priorities under the leadership of its new CEO. Committed to achieving tangible results, the company is prioritizing
Peptonic Medical AB (”Peptonic”) förtydligar bolagets kortsiktiga strategiska prioriteringar och framhäver vikten av försäljningstillväxt. Den nya VD:n understryker organisationens fokus på att accelerera försäljningen inom
Peptonic Medical AB (publ) today announced the launch of two new products on the home market in Sweden: VagiVital Menopause FSH Test and VagiVital Urinary
Peptonic Medical AB (publ) (“Peptonic”) announced today that Doz Apotek will include the company’s product Vernivia against bacterial vaginosis in the assortment in 51 of
Peptonic Medical AB (publ) (“Peptonic”) is extending the partnership with Farmasiet that will bring the entire VagVital product portfolio to the Norwegian market. Farmasiet, Norway’s
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented intimate wash, VagiVital Moisturizing V Cleanser, is being offered for sale in 293 Apoteket
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (”Peptonic”) today announced that the company has signed a non-exclusive distribution agreement with Al Fotune Medical Equipment LLC for United Arab Emirate concerning the product VagiVital VS Pro. ”Al Fotune is a medical device company
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented product for self-testing of bacterial vaginosis, VagiVital VS, is being offered for sale in
Today, November 2, 2023 the exercise period for warrants of series TO3 begins in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period lasts
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic CEO Erik Sundquist presented the company on Biostock Life Summit Event in Lund October 26, 2023. If you were unable to see the event
Peptonic Medical AB (publ) today announced that CEO Erik Sundquist will present the company at the BioStock Life Science Fall Summit in Lund, Sweden, on
Peptonic Medical AB (publ) today announced that it has received its first order in Central America from Windsor Pharmaceuticals. “It is gratifying that Windsor now
Peptonic Medical will present at the BioStock Life Science Fall Summit in Lund on October 25-26. Join us for our presentation at 15:30 on October 26th. Read more
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company has agreed with the world’s largest retail chain Walmart to begin selling Peptonic’s self-test for
Peptonic Medical AB (publ) (“Peptonic”) today announced that it has signed an exclusive agreement regarding VagiVital’s amniotic leak self-test with Savyon Diagnostics (“Savyon”) for the
At an extraordinary general meeting on August 21, Pharmiva’s shareholders approved the planned merger between Peptonic Medical AB (“Peptonic”) and Pharmiva AB (“Pharmiva”). The merger
GROUP 2023 SECOND QUARTER (April-June) 2023 FIRST HALF YEAR (April-June) Message from our CEO Important steps towards establishing a leading Swedish Femtech Company We are
Peptonic Medical AB (publ) today announces that Albert Lindgren has been appointed Chief Financial Officer (CFO) and member of Group Management. He will take up
PEPTONIC Medical AB today announced that the company has signed a license agreement with Swiss medical device company Prima Lab SA for the sale of
Peptonic Medical AB (publ) today announces that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) claim for a corporate fine for
The FemTech companies PEPTONIC medical AB (“Peptonic”), listed on Spotlight Stock Market, and Pharmiva AB (publ) (“Pharmiva”), listed on Nasdaq First North Growth Market, have
Peptonic Medical AB (publ) today announced that the application to patent its intimate cleanser in US will be approved on June 20th2023, this according to
Peptonic Medical AB (publ) today announced that an arbitration court in China has ruled in favor of Peptonic in a dispute with Yuanjia Biotechnology Co., Ltd.
Peptonic Medical (publ) announces that the distribution agreement with medtech company GMS Healthcare Group in the United Arab Emirates (UAE) expands with three additional VagiVital® products.
PEPTONIC Medical AB announces that the company has signed a license agreement with Swiss medical technology company Prima Lab SA regarding self-tests for urinary tract
Peptonic Medical AB (publ) today announced that the company has signed an exclusive agreement with Cetro Medical for distribution of VagiVital VS Pro and VagiVital AL
GROUP 2022 FIRST QUARTER (jan-mar) Word from our CEO It is with great joy we can report that the positive development of the core business,
Peptonic Medical (PMED:SS) today announced that it has signed a non-exclusive agreement with the medical technology company Siemens Healthineers for the distribution of Peptonic’s portfolio of diagnostic
Peptonic Medical (publ) today announced that Apotek Hjärtat is initiating sales of the company’s leading intimate care product VagiVital® AktivGel in most of its physical
The Nomination Committee of Peptonic Medical AB (publ) presents the following proposals for resolutions at the Annual General Meeting on May 24 2023, regarding the number of
GROUP 2022 FOURTH QUARTER (oct-dec) FULL YEAR 2022 (jan-dec) Before inventory adjustments that fully charge quarter 4 instead of being distributed over previous quarters. From
Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests
Peptonic Medical (publ) informed today that it’s wholly owned subsidiary Lune Group Oy has got an order from UN. The first of its kind. Earlier
Peptonic Medical (publ) informed today that it’s wholly owned subsidiary Lune Group Oy has won the Klarna Growth Award in the category “Small Business”. Lunette
Valberedningen för Peptonic Medical AB (publ) lägger fram följande förslag till beslut vid årsstämman den 24 maj 2022 avseende antalet ledamöter och val av styrelseledamöter.
Den 4 november 2021 offentliggjorde PEPTONIC Medical AB (publ) (“Bolaget” eller ”Peptonic”) att styrelsen hade föreslagit en företrädesemission om cirka 42 MSEK (”Företrädesemissionen”). Styrelsens förslag
Peptonic Medical (publ) announced today that its wholly owned daughter company Lune Oy Ltd has signed a marketing collaboration agreement with a Swedish company Peak
Peptonic Medical AB (publ) meddelar idag att dess helägda dotterbolag Lune Oy Ltd har tecknat ett marknadsföringssamarbetsavtal med det svenska företaget Peak Performance. I syfte
Peptonic Medical (publ) announced today that it has signed a Distribution Agreement with UCC Australia for the Australian market concerning 5 items in the Lunette
Peptonic Medical (publ) meddelade idag att man tecknat ett distributionsavtal med UCC för den australiska marknaden. Avtalet avser 5 artiklar i sortimentet från Lunette. UCC
Den 16 december 2021 bemyndigade den extra bolagsstämman styrelsen i Peptonic Medical AB (“Bolaget”), att besluta om att genomföra en nyemission av högst 63 879 879 aktier med företrädesrätt
Peptonic Medical (publ). Årsredovisningen för 2021 har idag blivit tillgänglig. Den finns att ladda hem här. Styrelse och ledning vill kommentera den anmärkningen från revisorn
Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Peptonic Medical Israel Ltd and CommonSense Marketing Inc are included from 2021-10-20. 2021 Fourth
Bokslutskommuniké Peptonic Medical AB (publ) org nr 556776-3064.(www.spotlightstockmarket.com, kortnamn: PMED) Koncern, Peptonic Medical Israel Ltd och CommonSense Marketing Inc är inkluderade från och med 2021-10-20.
Peptonic Medical (publ) announced today that it is now introducing VagiVital®️ range of hormone free treatments to the US market. VagiVital long term vision is to
Bolaget har tidigare meddelat att EBM inlett en utredning 2020 rörande grovt insiderbrott med anledning av åtgärder som Bolaget vidtagit inom ramen för ett finansieringsarrangemang
The Company has previously announced that the Swedish Economic Crime Authority initiated an investigation in 2020 regarding a serious insider crime due to measures that
Peptonic Medical (publ) meddelade idag att dess helägda dotterbolag Lune Group Oy Ltd har tecknat ett gemensamt marknadsföringsavtal med amerikanska företaget Womanizer. Ett strategiskt partnerskap
Peptonic Medical (publ) announced today that its wholly owned daughter company Lune Oy Ltd has signed a joint promotion agreement with American company Womanizer. A
At the Annual General Meeting on June 30, 2021, it was decided that the Chairman of the Board will contact the three largest shareholders in
Vid årsstämman den 30 juni 2021 beslutades att styrelsens ordförande tar kontakt med de tre röstmässigt största aktieägarna enligt Euroclears utskrift av aktieboken per den
Rättelse av tidigare utskickad pressrelease – Av misstag har tidigare utskick MAR märkts, vilket är felaktigt. Peptonic Medical AB (publ) (’Peptonic’ eller ’Bolaget’) meddelar idag
Peptonic Medical AB (publ) (’Peptonic’ eller ’Bolaget’) meddelar idag att styrelsens förslag enligt kallelsen till extra bolagstämman som hölls den 16 december 2021 godkändes enhälligt.
Peptonic Medical (publ) meddelade idag att LloydsApotek utökar sin distribution med ytterligare tre produkter ur Peptonics sortiment. Lloyds driver 75 apotek på ett 40-tal orter
Peptonic Medical (publ) announced today that LloydsApotek is expanding its distribution with three more products from Peptonic’s range. LloydsApotek operates 75 pharmacies in about 40
PEPTONIC medical AB (publ), 556776-3064, (”PEPTONIC” eller ”Bolaget”) har genom pressmeddelande den 4 november 2021 informerat om Bolagets avsikt att genomföra en företrädesemission av aktier
Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com, kortnamn: PMED). Koncern, Lune Group OY är inkluderad från och med 2020-06-03 2021 kvartal 3 (jul-sep) Omsättning
Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03 Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com ticker: PMED) Group, Lune Group
Peptonic Medical AB (publ) (“PMED” eller “Bolaget”) offentliggör idag den 4 november 2021 avsikten att genomföra en företrädesemission av units bestående av aktier och teckningsoptioner av serie
Peptonic Medical AB (publ) (“PMED” or “the Company”) announces today, November 4th , 2021, the intention to carry out a rights issue of units consisting of shares
Peptonic Medical (publ) meddelar idag att man tecknat ett tilläggsavtal med Orion Corporation i Finland. Tilläggsavtalet avser Peptonics Moisturizing V Cleanser för den finska marknaden
Peptonic Medical (publ) today announced that the company has signed a contract amendment with Orion Corporation in Finland. The amendment concerns Peptonic’s Moisturizing V Cleanser
The acquisition also includes the US-registered subsidiary CommonSense Marketing Inc, based in New York. During year 2020 CommenSense had sales of approximately $ 2 million. CommonSense
I förvärvet ingår även det USA-registrerade dotterbolaget CommonSense Marketing Inc med säte i New York. Föregående år hade CommenSense en omsättning motsvarande ca 2 miljoner US-dollar.
CommonSense has been under public administration since 2021-07-07. The company is focused on women’s health and has, among other things, CE-marked products for self-testing of
CommonSense står under offentlig förvaltning sedan 2021-07-07. Bolaget är inriktat på kvinnohälsa och har bland annat CE-märkta produkter för självtest av bakteriell vaginosis och svampinfektioner.
Peptonic Medical (publ) (‘Peptonic’ eller ‘bolaget’) informerar om ett förtydligande gällande uppsägningen av Yuanjia Biotechnology Co., Ltd. och registreringsprocessen av VagiVital®️ i Kina. Då det
Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. Peptonic Medical AB (publ) org nr 556776-3064(www.aktietorget.se ticker: PMED). Group, Lune Group OY
Peptonic Medical AB (publ) org nr 556776-3064(www.spotlightstockmarket.com, kortnamn: PMED) Koncern, Lune Group OY är inkluderad från och med 2020-06-03 2021 kvartal 2 (apr-jun) Omsättning produkter
